Skip to Content
Top

BY MD Anderson

Early findings from Phase I and Phase II clinical trials using a new class of drug to treat patients with triple-negative breast cancer are showing promising results. Known as poly (ADP-ribose) polymerase, or PARP inhibitors, these new agents received considerable attention at the American Society of Clinical Oncology meeting in June.

Cheryl Jolly, in the related story, is now enrolled in a Phase III trial, and her tumor is shrinking...

BY Judy Overton

Labor Day marked the sixth anniversary of Tom's diagnosis. Although his illness caught us off guard and reeled us from our comfortable spot...

BY Lorenzo Cohen, Ph.D.

People often do not make a distinction between the terms integrative medicine and alternative medicine. Below is the mission statement of...

BY Judy Overton

Once Tom was admitted to a local Houston hospital, a urologist and a team of medical personnel examined him. The lead doctor said the surgery to remove the mass and his left kidney would take place on Friday.

"Why wait three days?" I asked. "We don't want to rush into it," is what I recall him saying, although I'm certain he seemed perturbed that I asked.

He also confirmed that the mass was estimated...